Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD — Louisville, Kentucky

Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD is a clinical research site located in Louisville, Kentucky, United States 40207.

Crixeo Health Trust Score: 62/100 (FAIR). This profile has not yet been claimed by the site owner.

Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD has participated in 3 clinical trials with 1 currently active.

Therapeutic areas: Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia.

Sponsors: Pfizer, Seagen, a wholly owned subsidiary of Pfizer.

Sponsor Feasibility Report

Trust Score: 62/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD?

Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD has a Crixeo Trust Score of 62/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD conducted?

Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD has 3 clinical trials on record, with 1 currently active. Their work covers Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia.

Is Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD accredited by Crixeo Health?

Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.